Last updated: November 8, 2026
SYMPAZAN is Aquestive Therapeutics' branded clobazam oral film for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients age two and older. The product's commercial position depends on three factors: differentiation from generic clobazam tablets and suspension, reimbursement for an administration-friendly dosage form, and the duration of Aquestive's patent protection. Sympazan has strategic value within Aquestive's specialty-neurology portfolio, but it is a smaller commercial asset than the company's leading products and does not have publicly disclosed standalone revenue in SEC filings. [1][2]
What is SYMPAZAN and how does the drug work?
SYMPAZAN contains clobazam, a 1,5-benzodiazepine used with other medicines to treat seizures associated with Lennox-Gastaut syndrome. It is an oral soluble film placed on the tongue, where it dissolves without requiring a tablet to be swallowed with water.
| Attribute |
SYMPAZAN |
| Active ingredient |
Clobazam |
| Dosage form |
Oral soluble film |
| FDA sponsor |
Aquestive Therapeutics, Inc. |
| FDA application |
NDA 210833 |
| Initial FDA approval |
November 2018 |
| Indication |
Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome |
| Approved age |
Patients 2 years and older |
| Strengths |
5 mg, 10 mg, 20 mg |
| Primary differentiation |
Administration format and dosing flexibility |
| Main alternatives |
Generic clobazam tablets, oral suspension, ONFI |
The product does not introduce a new molecular entity. Its commercial case is based on delivery technology, patient and caregiver convenience, and potential use in patients who have difficulty swallowing tablets or require administration without water.
How large is the SYMPAZAN market?
The addressable market is the U.S. Lennox-Gastaut syndrome population treated with clobazam, not the entire epilepsy market. Lennox-Gastaut syndrome is a severe developmental epileptic encephalopathy that generally requires multiple antiseizure medicines. Clobazam is commonly used as an adjunctive therapy, creating a recurring prescription market but also exposing Sympazan to substitution by lower-cost generic products.
The principal market drivers are:
- Growth in diagnosis and specialist treatment of Lennox-Gastaut syndrome.
- Persistent use of clobazam in pediatric and adult patients.
- Caregiver demand for dosage forms that are easier to administer.
- Coverage decisions by commercial insurers, Medicaid, and pharmacy benefit managers.
- Ability to retain patients despite generic clobazam price competition.
The market is structurally constrained by the narrow indication and by the availability of generic clobazam. Sympazan's price premium must be justified through adherence, ease of administration, and patient-specific clinical utility rather than through superior clobazam pharmacology.
What is the financial trajectory of SYMPAZAN?
Aquestive reports product revenue at the company level and does not consistently disclose a complete standalone revenue series for Sympazan in its public filings. That limits product-level valuation precision. The company's reported financial trajectory is driven by a portfolio that includes Sympazan, Suboxone Film, Exservan, Libervant and other products, rather than by Sympazan alone. [1][2]
How does Sympazan contribute to Aquestive's revenue?
Sympazan is a commercial product with recurring sales, but it is not the central revenue engine of Aquestive's business. The company's financial profile has historically depended heavily on oral-film products with larger commercial markets, particularly buprenorphine and naloxone products. Sympazan's contribution is strategically relevant because it extends Aquestive's film technology into neurology, but the product's absolute revenue ceiling is limited by:
- The relatively small Lennox-Gastaut population.
- Generic clobazam competition.
- Payer utilization controls.
- A requirement for chronic adjunctive use.
- The existence of clobazam suspension and tablet alternatives.
Aquestive's filings describe the business through consolidated revenue, product sales, gross margin, operating expenses and pipeline milestones. They do not establish a reliable annual Sympazan revenue figure that can be separated from other products without company-specific segment disclosure. [1][2]
What financial factors determine Sympazan's profitability?
Sympazan's economics are influenced by net price, gross-to-net deductions, manufacturing scale and sales infrastructure. The oral-film manufacturing process can support product differentiation, but it also requires specialized production, quality control and packaging.
Key profitability variables include:
| Variable |
Effect on Sympazan |
| Wholesale acquisition price |
Determines the starting price before rebates and discounts |
| Reimbursement |
Controls access and prescription conversion |
| Medicaid rebates |
Can materially reduce net sales |
| Copay assistance |
Supports branded demand but increases commercial deductions |
| Manufacturing utilization |
Higher volume can improve fixed-cost absorption |
| Sales force allocation |
Determines the cost of maintaining neurology prescriber coverage |
| Generic substitution |
Compresses price and reduces market share |
| Patent duration |
Extends the period for premium pricing |
A higher prescription count does not necessarily produce proportional revenue growth if payers demand prior authorization, impose step edits, or require trial of generic clobazam.
What patents protect SYMPAZAN?
Sympazan is protected by a combination of product, formulation, manufacturing and method-of-use rights rather than by compound exclusivity. Clobazam itself is an old active ingredient, so the defensible intellectual property centers on the oral-film delivery system and related pharmaceutical compositions.
Aquestive has stated that its oral-film technology is supported by a broad patent estate covering film composition, drug loading, manufacturing and administration. The relevant rights may include patents associated with:
- Film-forming polymers and plasticizers.
- Uniform distribution of clobazam within the film.
- Dosage-unit dimensions and drug loading.
- Rapid dissolution in the oral cavity.
- Manufacturing and coating processes.
- Use of clobazam film for seizure treatment.
The U.S. Food and Drug Administration's Orange Book is the controlling public source for patents listed for an approved drug application. Orange Book entries, patent expiration dates and pediatric exclusivity should be reviewed against the current FDA listing for NDA 210833 before making a launch or litigation decision. [3]
How strong is the Sympazan patent estate?
The estate is stronger against an identical or technically close clobazam oral film than against conventional generic tablets. A competitor can reduce infringement risk by selecting a different dosage form, film composition, manufacturing process or claim design.
Patent strength is therefore mixed:
| Protection category |
Relative strength |
| Clobazam active ingredient |
Weak or unavailable because the compound is old |
| Oral-film composition |
Potentially meaningful |
| Film manufacturing process |
Meaningful if claims are difficult to design around |
| Method of treating Lennox-Gastaut syndrome |
Narrower and vulnerable to inducement or label-based challenges |
| Tablet or suspension substitutes |
Generally outside the core Sympazan formulation claims |
| Trade secrets and process know-how |
Can increase practical barriers but do not block all competitors |
The commercial value of the estate depends on claim scope, validity, Orange Book listing status, prosecution history and whether a generic applicant can certify that it will not practice the asserted claims.
When does SYMPAZAN lose exclusivity?
Sympazan's regulatory exclusivity and patent exclusivity are separate.
FDA approval in 2018 did not create new chemical entity exclusivity because clobazam was already approved. The product may receive protection through formulation-related patents, orphan-drug provisions if applicable, pediatric exclusivity and other regulatory mechanisms, but those protections must be assessed separately.
A generic applicant seeking approval through an abbreviated new drug application could challenge listed patents through a Paragraph IV certification. A Paragraph IV notice can trigger litigation and a potential 30-month stay of FDA approval under the Hatch-Waxman framework, subject to statutory exceptions and litigation outcomes. [4]
The relevant launch scenarios are:
| Scenario |
Commercial result |
| No ANDA challenge |
Sympazan retains market protection until applicable patent barriers expire |
| Paragraph IV challenge not litigated |
Generic approval may proceed after statutory requirements are met |
| Paragraph IV litigation with timely suit |
FDA approval can be stayed for up to 30 months, subject to court action |
| Patents invalidated or not infringed |
Generic entry can occur before nominal patent expiration |
| Settlement with licensed entry |
Entry date depends on the agreement |
| Non-infringing alternative formulation |
Competitor may enter without copying every protected feature |
No broad claim should be made that Sympazan is protected until a particular date without reconciling the current Orange Book listing, patent-family members, terminal disclaimers and any pediatric extension.
Are there Paragraph IV challenges to SYMPAZAN?
Publicly available information must distinguish a formal Paragraph IV notice from ordinary competitive activity. Generic clobazam products already create commercial pressure, but that does not by itself establish an ANDA challenge to Sympazan's oral-film patents.
A Paragraph IV case would normally appear through a combination of:
- A company disclosure by Aquestive.
- Federal court docket activity.
- An FDA patent listing and certification record.
- An ANDA applicant's litigation filing or notice.
- A settlement or license disclosure.
The existence of generic clobazam tablets or suspension does not prove that a generic applicant has challenged Sympazan's film formulation patents. This distinction matters because a conventional clobazam generic can compete with Sympazan without infringing every film-specific patent claim.
What is the FDA and Orange Book status of SYMPAZAN?
SYMPAZAN is FDA-approved under NDA 210833 for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients two years of age and older. [5]
The Orange Book identifies approved drug products, therapeutic-equivalence information and patent or exclusivity data submitted by sponsors. For Sympazan, the commercial questions are:
- Which patents are currently listed against NDA 210833?
- Are the listed claims directed to the film, composition, method of use or manufacturing?
- Are any patents expired, delisted or subject to terminal disclaimers?
- Does an ANDA applicant need a Paragraph IV certification?
- Is pediatric exclusivity attached to any listed protection?
Orange Book status is more important than marketing language because it determines the formal patent information available to an ANDA applicant and affects the timing of FDA approval.
What formulations are protected by SYMPAZAN patents?
The primary protected formulation is the clobazam oral film. The commercial and technical differentiation includes:
- A thin, flexible film dosage unit.
- Controlled drug loading.
- Oral dissolution without water.
- Packaging designed for unit-dose administration.
- Film manufacturing that supports dose uniformity.
- Strength-specific dosing for 5 mg, 10 mg and 20 mg products.
The formulation may be valuable for pediatric patients, patients with dysphagia and caregivers who need rapid administration during routine dosing. It is less likely to command a durable premium where patients can reliably use tablets or suspension and payers apply substitution policies.
How does SYMPAZAN compare with generic clobazam?
| Factor |
SYMPAZAN |
Generic clobazam tablets or suspension |
| Active ingredient |
Clobazam |
Clobazam |
| Delivery |
Oral film |
Tablet or liquid |
| FDA indication |
Lennox-Gastaut syndrome adjunctive therapy |
Product-specific labeling |
| Price |
Branded premium |
Lower-cost generic pricing |
| Administration |
Does not require swallowing a tablet or water |
May be less convenient for some patients |
| Payer position |
Subject to branded-drug controls |
Usually preferred |
| Patent exposure |
Film and formulation patents |
Usually avoids film-specific claims |
| Switching risk |
High where reimbursement favors generics |
Lower acquisition cost |
Sympazan's strongest commercial segment is patients for whom administration convenience affects adherence or treatment continuity. Its weakest segment is stable patients who tolerate generic tablets and face payer-mandated substitution.
What licensing deals and partnerships affect Sympazan?
Aquestive's major strategic value is its proprietary PharmFilm technology and its ability to commercialize oral-film products through partnerships and internal products. Public disclosures have emphasized development and commercialization arrangements across the broader portfolio, including agreements involving other products and technology programs. [1][2]
No major third-party licensing transaction should be attributed specifically to Sympazan without a contract or SEC disclosure that identifies the product. The absence of a separately disclosed Sympazan licensing transaction means the product's financial trajectory is primarily an internal commercialization and portfolio-allocation question.
What litigation affects SYMPAZAN?
Sympazan litigation risk has two forms:
Patent litigation
This would arise from an ANDA Paragraph IV challenge or a dispute involving formulation, manufacturing or method-of-use claims. The key outcome is whether the challenger can obtain FDA approval before the relevant patents expire or are invalidated.
Commercial and regulatory litigation
Aquestive could also face disputes involving reimbursement, product liability, manufacturing quality or promotional conduct. These risks are common to branded prescription drugs but are not equivalent to patent litigation.
A litigation assessment should rely on federal docket records, company 10-K risk disclosures, FDA records and Orange Book data. A generic clobazam market does not establish that a Sympazan-specific patent case is pending.
What generic launch risks exist for SYMPAZAN?
The highest risk is substitution by generic clobazam in patients who do not require the film format. The most important launch pathways are:
- A generic oral film that challenges formulation patents.
- A conventional generic that captures patients through lower cost.
- A payer policy that requires generic clobazam before Sympazan.
- A branded competitor with a different administration technology.
- A court decision narrowing or invalidating formulation claims.
A generic oral film would present the most direct patent threat. Conventional tablets and suspension present the larger practical market threat because they can erode prescriptions without duplicating the same dosage form.
What manufacturing and geographic barriers protect SYMPAZAN?
Sympazan's practical barriers include specialized film manufacturing, process validation, dose uniformity, packaging, stability testing and regulatory documentation. These barriers can slow a competitor but do not replace enforceable patent rights.
U.S. protection is the most commercially significant because the product is approved and marketed in the United States. International protection depends on country-specific approvals, patent grants, claim scope and reimbursement. The existence of a U.S. patent does not establish equivalent protection in Europe, Canada, Japan or other markets.
What is the investment outlook for SYMPAZAN?
Sympazan is best viewed as a stable specialty product with moderate growth potential and meaningful substitution risk. The product can generate recurring cash flow if it retains reimbursement and maintains a defined patient population that values oral-film administration. It is unlikely to become a large growth asset without expanded indications, stronger payer coverage, additional age or use claims, or broader adoption of the oral-film format.
The main value drivers are:
- Durable market access.
- Retention of patients who benefit from film administration.
- Absence of a successful oral-film Paragraph IV challenge.
- Manufacturing efficiency.
- Portfolio cross-selling through the same specialty-neurology infrastructure.
The main downside drivers are:
- Generic substitution.
- Net-price erosion.
- Narrow indication size.
- Weak or expiring formulation claims.
- High commercialization costs relative to product sales.
Key Takeaways
- SYMPAZAN is a clobazam oral film approved in 2018 for adjunctive treatment of Lennox-Gastaut syndrome.
- Its differentiation is dosage form and administration convenience, not a novel active ingredient.
- Generic clobazam tablets and suspension are the primary commercial competitors.
- Aquestive does not provide a consistently separable standalone Sympazan revenue series in public SEC reporting.
- The product's patent value is concentrated in oral-film composition, manufacturing and related method-of-use claims.
- A Paragraph IV challenge would create the most direct patent-entry risk, but generic clobazam already creates substantial substitution pressure.
- Sympazan is strategically useful to Aquestive's specialty portfolio but has a limited addressable market and a lower growth ceiling than broader oral-film products.
FAQs
Is SYMPAZAN the same as ONFI?
Both products contain clobazam and are used in Lennox-Gastaut syndrome, but Sympazan is an oral film while ONFI was marketed as an oral suspension and tablet product. Their formulation and patent positions are not identical.
Can patients substitute generic clobazam for SYMPAZAN?
A prescriber or pharmacist may consider generic clobazam when clinically appropriate, but the products have different dosage forms. Generic substitution depends on product-specific therapeutic-equivalence rules, state law, payer policy and prescriber direction.
Does SYMPAZAN have orphan-drug exclusivity?
The existence and duration of orphan-drug exclusivity must be confirmed in the FDA's current orphan-designation and exclusivity records. Orphan exclusivity is separate from formulation patents and does not automatically block every clobazam product.
Who manufactures SYMPAZAN?
Sympazan is commercialized by Aquestive Therapeutics. Manufacturing may involve company facilities and qualified third-party operations disclosed in regulatory filings and product supply documents.
Is SYMPAZAN approved outside the United States?
U.S. FDA approval does not establish approval in other jurisdictions. International availability depends on separate applications, local regulatory decisions, patents and commercial agreements.
References
-
Aquestive Therapeutics, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023 (Form 10-K). U.S. Securities and Exchange Commission.
-
Aquestive Therapeutics, Inc. (2024). Quarterly reports and investor disclosures. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments and abbreviated new drug applications. https://www.fda.gov/drugs
-
U.S. Food and Drug Administration. (2018). SYMPAZAN prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
